11:42 AM EST - Helix BioPharma Corp. : announced it has completed its interim review of the Company's ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland L-DOS47 was well tolerated for all patients treated within all cohorts. None of the treatment-related adverse events reported to date has met the definition of a dose-limiting toxicity. Helix BioPharma Corp.
shares T.HBP are trading up $0.02 at $1.30.
